BackGenetics Generation Advancement Overview

Genetics Generation Advancement EBIT

Track Genetics Generation Advancement's EBIT ($-3.9M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$1.54M
↓ 265.84% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

-$3.94M
↓ 122.22% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Genetics Generation Advancement (4160.TWO) FAQ

As of the most recent data (September 2026), 4160.TWO shows a EBIT of $-3.9M. That compares with $18M in the prior-year period — down 122.2% year over year. That is below the sector sector average of $2.3T. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 4160.TWO's EBIT is now $-3.9M (was $18M) — a 122.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Genetics Generation Advancement is outperforming or lagging.

The its sector sector average EBIT is about $2.3T. Genetics Generation Advancement is at $-3.9M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how 4160.TWO stacks up against individual peers as well.

Tracking 4160.TWO's ebit over time shows whether Genetics Generation Advancement is scaling, shrinking, or reshaping that part of the business. The current reading is $-3.9M That compares with $18M in the prior-year period — down 122.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Genetics Generation Advancement's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-3.9M) with ownership activity and broader fundamentals.

Questions & Answers